Precision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy

Reuters

05-15

Precision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy

DURHAM, N.C., May 14, 2025 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company, has announced the strategic prioritization and acceleration of its innovative PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD). This development targets dystrophin mutations within the common 'hot spot' region between exons 45-55. The company highlighted compelling preclinical evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, underscoring PBGENE-DMD's potential to durably improve muscle function. A conference call discussing this advancement is scheduled for May 15, 2025, at 8:00 AM ET, accessible via a live audio webcast on Precision BioSciences' investor site.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-071551), on May 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535885918"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535885918\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535885918?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 04:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535885918","market":"nz","top_or_hot":-1,"title":"Precision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Precision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DURHAM, N.C., May 14, 2025 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company, has announced the strategic prioritization and acceleration of its innovative PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD). This development targets dystrophin mutations within the common 'hot spot' region between exons 45-55. The company highlighted compelling preclinical evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, underscoring PBGENE-DMD's potential to durably improve muscle function. A conference call discussing this advancement is scheduled for May 15, 2025, at 8:00 AM ET, accessible via a live audio webcast on Precision BioSciences' investor site.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-071551), on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-15 04:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Precision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DURHAM, N.C., May 14, 2025 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company, has announced the strategic prioritization and acceleration of its innovative PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD). This development targets dystrophin mutations within the common 'hot spot' region between exons 45-55. The company highlighted compelling preclinical evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, underscoring PBGENE-DMD's potential to durably improve muscle function. A conference call discussing this advancement is scheduled for May 15, 2025, at 8:00 AM ET, accessible via a live audio webcast on Precision BioSciences' investor site.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-071551), on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL1jTYxL:1","article_id":"2535885918","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535885918","pubTimestamp":1747255596,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"DURHAM, N.C., May 14, 2025 -- Precision BioSciences, Inc. , a clinical-stage gene editing company, has announced the strategic prioritization and acceleration of its innovative PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy . This development targets dystrophin mutations within the common 'hot spot' region between exons 45-55. The company highlighted compelling preclinical evidence at the American Society of Gene and Cell Therapy  Annual Meeting, underscoring PBGENE-DMD's potential to durably improve muscle function. A conference call discussing this advancement is scheduled for May 15, 2025, at 8:00 AM ET, accessible via a live audio webcast on Precision BioSciences' investor site.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DTIL":"Precision Biosciences Inc"},"translate_title":"Precision BioSciences宣布加速PBGENE-DMD基因编辑方法治疗杜氏肌营养不良症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DTIL":0.9},"content_text":"Precision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy\n    \n\n        DURHAM, N.C., May 14, 2025 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company, has announced the strategic prioritization and acceleration of its innovative PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD). This development targets dystrophin mutations within the common 'hot spot' region between exons 45-55. The company highlighted compelling preclinical evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, underscoring PBGENE-DMD's potential to durably improve muscle function. A conference call discussing this advancement is scheduled for May 15, 2025, at 8:00 AM ET, accessible via a live audio webcast on Precision BioSciences' investor site.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-071551), on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}